For How Long Should We Use Symptomatic Therapies to Treat People with Alzheimer Disease?

Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006;(1):CD005593.

Gauthier S Patterson C Chertkow H Recommendations of the 4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD4). Can Geriatr J. 2012;15(4):120–126; and simultaneously in Can J Neurol Sci. 2012;39(6 Suppl 5):S1–S8.

Raina P Santaguida P Ismaila A Effectiveness of cholinesterase inhibitors and memantine for treating dementia: Evidence review for a clinical practice guideline. Ann Intern Med. 2008;148(5):379–397.

Hogan DB . Long-term efficacy and toxicity of cholinesterase inhibitors in the treatment of Alzheimer disease. Can J Psychiatry. 2014;59(12):618–623.

Maxwell CJ Stock K Seitz D Persistence and adherence with dementia pharmacotherapy: Relevance of patient, provider, and system factors. Can J Psychiatry. 2014;59(12):624–631.

Rockwood K. Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2004;75(5):677–685.

Rockwood K MacKnight C. Assessing the clinical important of statistically significant improvement in anti-dementia drug trials. Neuroepidemiology. 2011;20(2):51–56.

Rockwood K Fay S Jarrett P Effect of galantamine on verbal repetition in AD: A secondary analysis of the VISTA trial. Neurology. 2007;68(14):1116–1121.

Rockwood K. The importance of measuring executive function when studying the effects of cognition-enhancing agents. Ann Intern Med. 2008;149(5):358–359.

Herrmann N Black SE Li A Discontinuing cholinesterase inhibitors: Results of a survey of Canadian dementia experts. Int Psychogeriatr. 2011;23(4):539–545.

Rosen WG Mohs RC Davis KL . A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141(11):1356–1364.

US Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research. Guidance for industry Alzheimer's disease: Developing drugs for the treatment of early stage disease [Internet]. Silver Spring (MD): US Department of Health and Human Services; 2013 Feb [cited 2014 Jul 3]. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM338287.pdf. p 5.

Cummings J Gould H Zhong K. Advances in designs for Alzheimer's disease clinical trials. Am J Neurodegener Dis. 2012;1(3):205–216.